Brain-computer interface relieves chronic chemotherapy-induced peripheral neuropathy: A randomized, double-blind,...

Area of Science:

• Neuroscience
• Oncology
• Rehabilitation Medicine

Background:

• Chemotherapy-induced peripheral neuropathy (CIPN) is a chronic, debilitating condition for cancer survivors.
• Previous studies indicated neurofeedback (a closed-loop brain-computer interface [BCI]) efficacy in treating CIPN.
• The current study hypothesized BCI superiority over placebo and waitlist controls for CIPN alleviation.

Purpose of the Study:

• To evaluate the efficacy of BCI compared to placebo and waitlist controls in reducing CIPN symptoms.
• To determine if changes in brain activity predict symptom reduction.
• To assess the long-term effects of BCI treatment on CIPN.

Main Methods:

• A randomized controlled trial involving breast cancer survivors with CIPN.
• Participants were assigned to BCI, placebo control (PLC), or waitlist control (WLC) groups.
• Treatment involved 20 sessions of BCI or PLC, with outcomes assessed post-treatment and at 1-month follow-up.

Main Results:

• Both BCI and PLC groups showed significant symptom reduction compared to WLC.
• The BCI group exhibited a larger effect size than the PLC group.
• Symptom improvement persisted at 1 month only in the BCI group, with brain activity changes predicting these outcomes.

Conclusions:

• BCI is a promising treatment for CIPN, offering potentially longer-lasting relief than placebo interventions.
• Understanding placebo effects is crucial, but BCI demonstrates specific therapeutic benefits for CIPN.
• Neurofeedback via BCI can modify brain activity to alleviate persistent nerve pain in cancer survivors.